Determining calpain-2 expression in ovarian cancer patients prior to platinum-based chemotherapy may identify those patients whose tumours are at high risk of developing resistance to the chemotherapy regimen and identification of such individuals will allow more rigorous follow-up or alternate treatment regimens to be considered. The gene discussed is CAPN2; the disease is ovarian carcinoma.